Page last updated: 2024-12-08

hydrastine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID197835
CHEMBL ID1256919
CHEBI ID69919
SCHEMBL ID337253
MeSH IDM0060453

Synonyms (78)

Synonym
BRD-K02715688-003-03-5
NCI60_003057
BPBIO1_000466
tnp00262
NCGC00017326-01
PRESTWICK3_000581
PRESTWICK2_000581
BSPBIO_000422
(3s)-6,7-dimethoxy-3-[(5r)-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3h-isobenzofuran-1-one
hydrastine
(-)-.beta.-hydrastine
6,7-dimethoxy-3-[(5r)-5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-, (3s)-
nsc646664
(1r,9s)-(-)-.beta.-hydrastine
118-08-1
einecs 204-233-0
phthalide, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-
brn 0098575
l-hydrastine
6,7-dimethoxy-3-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinoline-5-yl)-1(3h)-isobenzo furan
beta-hydrastine
PRESTWICK0_000581
SPBIO_002641
PRESTWICK1_000581
HMS2092I18
60594-55-0
(+/-)-|a-hydrastine
(3s)-6,7-dimethoxy-3-[(5r)-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3h-2-benzofuran-1-one
3-((5r)-6-methyl(5,6,7,8-tetrahydro-2h-1,3-dioxoleno[4,5-g]isoquinolin-5-yl))( 3s)-6,7-dimethoxy-3-hydroisobenzofuran-1-one
(-)-hydrastine
hydrastine [usp]
(1r,9s)-beta-hydrastine
(-)-beta-hydrastine
unii-8890v3217x
nsc 757430
8890v3217x ,
4-27-00-06833 (beilstein handbook reference)
CHEMBL1256919
nsc-757430
chebi:69919 ,
cas-118-08-1
dtxcid905409
tox21_200686
dtxsid9025409 ,
NCGC00258240-01
pharmakon1600-01500687
nsc757430
hydrastine (1r 9s)
(-)-|a-hydrastine
(1r,9s)-(-)-beta-hydrastine
phthalide (s)-6,7-dimethoxy-3-(r)-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-
hydrastine (constituent of goldenseal) [dsc]
hydrastine [who-dd]
hydrastine [usp-rs]
hydrastine [mi]
(s)-6,7-dimethoxy-3-(r)-(6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3h)-one
CCG-208523
SCHEMBL337253
CS-4396
AKOS024282347
hydrastine (1r, 9s)
HY-B0927
J-003701
bdbm50027777
hydrastine, united states pharmacopeia (usp) reference standard
hydrastin
SBI-0206699.P002
(-)-b-hydrastine
(s)-6,7-dimethoxy-3-((r)-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3h)-one
(+/-)-beta-hydrastine
BRD-K02715688-001-01-3
(1r,9s)-b-hydrastine(-)-b-hydrastine
(1r,9s)-b-hydrastine
(+)-b-hydrastinehcl
(s)-6,7-dimethoxy-3-(r)-(6-methyl-5,6,7,8-tetrahydro-(1,3)dioxolo(4,5-g)isoquinolin-5-yl)isobenzofuran-1(3h)-one
hydrastine (usp-rs)
hydrastine (constituent of goldenseal)
(1r,9s)-(-)- beta -hydrastine

Research Excerpts

Overview

Hydrastine is a phthalide isoquinoline alkaloid, isolated from Corydalis stricta.

ExcerptReferenceRelevance
"(+)-Hydrastine is a phthalide isoquinoline alkaloid, isolated from Corydalis stricta."( (+)-Hydrastine, a potent competitive antagonist at mammalian GABAA receptors.
Huang, JH; Johnston, GA, 1990
)
1.32

Treatment

ExcerptReferenceRelevance
"Treatment of hydrastine with the fermentation broth of Polyporous brumalis (ATCC 34487) as a model for mammalian metabolism, gave a new alkaloid, (1S)-hydroxyhydrastine."( Microbial transformation of the phthalideisoquinoline alkaloid, (-)-beta-hydrastine.
Ferreira, D; Herath, WH; Khan, IA, 2003
)
0.9

Toxicity

ExcerptReferenceRelevance
" The presence of Goldenseal root powder in dietary supplements and the topical application of Goldenseal preparations raise the possibility that an adverse phototoxic reaction may result from an interaction between its constituent alkaloids and light in exposed tissues."( Photochemistry and photocytotoxicity of alkaloids from Goldenseal (Hydrastis canadensis L.). 2. Palmatine, hydrastine, canadine, and hydrastinine.
Bilski, P; Chignell, CF; He, YY; Inbaraj, JJ; Kukielczak, BM; Sik, RH, 2006
)
0.55

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters for hydrastine were calculated using noncompartmental methods."( Hydrastine pharmacokinetics and metabolism after a single oral dose of goldenseal (Hydrastis canadensis) to humans.
Barone, G; Fifer, EK; Gupta, PK; Gurley, BJ; Hendrickson, HP, 2015
)
2.14

Compound-Compound Interactions

ExcerptReferenceRelevance
"Botanical medicines are frequently used in combination with therapeutic drugs, imposing a risk for harmful botanical-drug interactions (BDIs)."( An ex vivo approach to botanical-drug interactions: a proof of concept study.
Gurley, BJ; Markowitz, JS; Munoz, J; Wang, X; Zhu, HJ, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.55730.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency13.54640.003041.611522,387.1992AID1159552
pregnane X nuclear receptorHomo sapiens (human)Potency30.32660.005428.02631,258.9301AID1346982
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency39.81070.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency3.16230.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency25.11890.00636.904339.8107AID883
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.39810.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency25.11890.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Ki110.00000.00011.41629.9000AID589155
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID589086Mechanism based inhibition of human cytochrome P450 2C9 measured by diclofenac 4-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID589155Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone beta-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID397122Inhibition of HIV1 RT
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID589090Mechanism based inhibition of human cytochrome P450 2D6 measured by bufurarol 1'-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (25.93)18.7374
1990's5 (9.26)18.2507
2000's22 (40.74)29.6817
2010's12 (22.22)24.3611
2020's1 (1.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.61 (24.57)
Research Supply Index4.08 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index47.86 (26.88)
Search Engine Supply Index1.95 (0.95)

This Compound (36.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]